Pharmaceutical prices are expected to rise by 3.35% in 2026, according to Vizient’s latest Spend Management Outlook report, released in July.
The report found that price pressures are easing in certain areas due to biosimilar competition, especially with respect to drugs such as Humira and Stelara. High-use inpatient medications are also expected to see price declines. Pediatric drugs are expected to have the highest inflation rate, at 3.93%, while prices in the self-administered medication segment dropped from 4.53% to 3.3%.
Autoimmune and inflammatory therapies now represent the largest share of pharmacy spend among Vizient members, overtaking oncology, according to the report. Immune globulin products have become the top drugs by spend.
The report noted that pharmaceutical tariffs were not factored into the 2026 projection.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
